“Repeat measurement drives quality improvement, so participation in ePRaSE must become routine practice.”
Alec Price-Forbes National Chief Clinical Information Officer (CCIO), NHS England
What is ePRaSE?
The Electronic Prescribing Risk and Safety Evaluation (ePRaSE) is an NHS-led web-based self-assessment tool that helps trusts understand how well their ePrescribing (EP) systems are configured and maintained to mitigate known prescribing risks.
ePRaSE allows organisations to view their own results immediately to identify potential areas of prescribing risk, and at the end of each annual campaign to benchmark performance against national data.
The ePRaSE Cycle
The ePRaSE assessment process is cyclical, allowing for continuous evaluation, interpretation, and improvement in ePrescribing practices.
An annual 4-stage process driving continuous system assessment and national benchmarking.
Why take part?
- High-volume risks: Medicines are one of the highest-volume sources of reported patient-safety incidents.
- Structured evaluation: ePRaSE provides a structured, evidence-based assessment of how effectively EP systems may prevent high-risk prescribing errors.
- Benchmarking & priorities: Trusts receive trust-level reports and national benchmarking to support prioritisation and investment.
- Paediatric coverage: The latest release includes paediatric-specific prescribing scenarios, supporting assessment in this higher-risk area of care.